StockData

Anika Therapeutics vs Beta Bionics

ANIK and BBNX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANIK and BBNX compare

Beta Bionics is the larger company, worth 4.7 times as much as Anika Therapeutics ($800M against $172M).

Beta Bionics grew revenue faster over the last twelve months (43.7% versus 5.3% for Anika Therapeutics).

Anika Therapeutics keeps more of each dollar of sales as profit, with a net margin of −3.1% compared with −65.3% at Beta Bionics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANIKBBNX
Size and price
Market cap$172M$800M
Share price$12.85$14.72
Change, 1 year28.6%−45.8%
Change, 5 years−67.6%–
Beta (5Y)1.061.27
Employees235420
StockData Score
Total score1111
Valuation score12 (better)
Growth score12 (better)
Performance score3 (better)1
Health score66
Dividend score00
Valuation
P/S1.4× (better)6.3×
P/B1.3× (better)2.0×
EV/EBITDA267×–
P/FCF306×–
FCF yield0.33% (better)−8.2%
Fair value–$15.29
Margin of safety–3.7%
Growth
Revenue growth (TTM)5.3%43.7% (better)
Revenue growth, 5Y average−2.9%–
Profitability
Gross margin62.2% (better)58.6%
Operating margin−4.2% (better)−72.7%
Net margin−3.1% (better)−65.3%
FCF margin0.47% (better)−51.8%
Return on equity−2.7% (better)−23.9%
Return on invested capital−4.8% (better)−64.4%
Financial health
Debt / equity0.000.00
Current ratio4.488.92 (better)
Altman Z-score3.7510.25 (better)
Piotroski F-score66
Dividends and buybacks
Buyback yield8.8%–
Shareholder yield8.8% (better)0.00%
Ownership
Held by institutions91.9%88.2%
Held by insiders16.9%9.3%
Insider net buying, 12 months$264K (better)−$5.6M
Short interest, % of float2.9%10.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.